Oasmia Pharmaceutical AB (publ) - Special Call Transcript
()-
Thank you, and good afternoon, everyone. I'm very pleased to hear that we have over 100 participants on this webcast. So really thank you for that. So this morning, we announced the acquisition of Global development and commercialization rights for Cantrixil, a clinical stage ovarian cancer program, building, therefore, critical mass in our oncology pipeline. Over the course of the next hour or so, I'm looking forward to sharing with you the strategic rationale for this move and our excitement about it as we believe it marks an important milestone in Oasmia transformation. And as usual, we will be hosting a Q&A session at the end of this presentation.
Slide 2, that I will not ask you to read. Slide 3. So today, I am joined by Dr. Reinhard Koenig, who is our acting Chief Scientific Officer, who has been working for quite some time for Oasmia. And since this is the first time that you hear Reinhard, I would kindly ask him to present himself in a few words. Reinhard, the floor is yours.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |